Showing 3721-3730 of 4107 results for "".
- Mission Pharmacal Unveils New Lotion for Seborrheic Dermatitishttps://practicaldermatology.com/news/20140930-mission_pharmacal_unveils_new_lotion_for_seborrheic_dermatitis/2459100/To help bring a treatment option to people afflicted with common skin disorders including seborrheic dermatitis (SD), Mission Pharmacal Company has unveiled Ovace Plus Lotion (sodium sulfacetamide 9.8%). Ovace Plus Lotion joins Ovace Plus Wash (sodium sulfacetamide 10%) Cleansing Gel and Ovace Plus
- GSK Presents Updated Results from Phase III BREAK-3 Study of Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140929-gsk_presents_updated_results_from_phase_iii_break-3_study_of_tafinlar_dabrafenib/2459102/Results from the planned analysis of the Phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma show benefit for the use of GSK's Tafinlar (dabrafenib) over dacarbazine (DTIC). Forty-five percent of patients treated with dabrafenib only were alive at two
- Provectus ESMO Presentation: Ablative, Bystander Effects Of PV-10https://practicaldermatology.com/news/20140929-provectus_esmo_presentation_ablative_bystander_effects_of_pv-10/2459103/Provectus Biopharmaceuticals, Inc.'s data featured in a presentation during the European Society For Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, show PV-10 has a higher rate of response in injected tumors through its ablative effect, and that the durability of response as well as the
- Foamix Pharmaceuticals Ltd. Closes Initial Public Offeringhttps://practicaldermatology.com/news/20140924-foamix_pharmaceuticals_ltd_closes_initial_public_offering/2459104/Foamix Pharmaceuticals Ltd. Closes Initial Public Offering A total of 6.7 million ordinary shares were sold at a price to the public of $6.00 per share. In addition, Foamix has granted the underwriters a 30 day option to purchase up to 1,005,000 additional ordinary shares. The sha
- Celgene's Otezla Approved for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140924-celgenes_otezla_approved_for_moderate_to_severe_plaque_psoriasis/2459107/The FDA has approved Celgene's Otezla (apremilast), an oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Otezla is the first and only PDE4 inhibitor approved for th
- Medimetriks Pharmaceuticals Announces New Members Elected to Board of Directorshttps://practicaldermatology.com/news/20140923-medimetriks_pharmaceuticals_announces_new_members_elected_to_board_of_directors/2459108/Andrew Lary and William Resnick have been elected as independent directors of the Board of Directors of
- Cynosure Acquires Assets of RF Medical Device Manufacturer Ellman International, Inc.https://practicaldermatology.com/news/20140910-cynosure_acquires_assets_of_rf_medical_device_manufacturer_ellman_international_inc/2459121/Cynosure, Inc., which specializes in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, has acquired the assets of Ellman International, Inc. for approximately $13.2 million in cash. In addition, Cynosure assumed certain contractual and current liab
- Goldfaden MD Named 2014 CPG Editor's Choice Award Finalist by Informa's SupplySidehttps://practicaldermatology.com/news/20140908-goldfaden_md_named_2014_cpg_editors_choice_award_finalist_by_informas_supplyside/2459126/Informa Exhibitions has named Light Treatment “Dark Spot Corrector” as one of its finalists for the 2014 SupplySide CPG Editor's Choice Awards. Five 2013 consumer packaged goods (CPG) products were selected by the SupplySide editorial team for achievements in innovation and market impact in 20 dif
- The American Society of Laser Medicine & Surgery will Host Two Laser Aesthetics Courses in Fall 2014https://practicaldermatology.com/news/20140904-the_american_society_of_laser_medicine__surgery_will_host_two_laser_aesthetics_courses_in_fall_2014/2459128/In response to the success of its West Coast course, held annually at the Beckman Laser Institute in Irvine, CA, the American Society of Laser Medicine & Surgery (ASLMS) is initiating an East Coast Laser Aesthetics Course. The courses are designed for anyone who desires to have a deeper u
- FDA Approves Keytruda for Advanced Melanomahttps://practicaldermatology.com/news/20140904-fda_approves_keytruda_for_advanced_melanoma/2459129/The FDA granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.Keytruda is the first approved drug that blocks a cellular pathway known as PD-1, which restricts the